Effect of Early High-Dose Recombinant Human Erythropoietin on Behavior and Quality of Life in Children Aged 5 Years Born Very Preterm
Authors: Picotti Eleonora , Reinelt Tilman , Koller Brigitte , Bucher Hans Ulrich , Rüegger Christoph M. , Fauchère Jean-Claude , Natalucci Giancarlo ,   Swiss EPO Neuroprotection Trial Group, Zellinger Georg , Pasquier Sylviane , Capone Andrea , Bührer Christoph , Glanzmann René , Schulzke Sven , Weber Peter , Scharrer Brigitte , Bär Walter , Keller Elmar , Killer Christa , Pfister Riccardo , Krämer Karin , Hüppi Petra S , Borradori-Tolsa Cristina , Latal Beatrix , Bucher Hans Ulrich , Fauchère Jean-Claude , Welmann Sven , Koller Brigitte , Natalucci Giancarlo 
Published: December 2022

Importance

In light of the promising neuroprotective properties of recombinant human erythropoietin (RHEpo), the Swiss EPO Neuroprotection Trial was started to investigate its effect on neurodevelopment in very preterm infants. The results of the primary and secondary outcome analysis did not show any effect of RHEpo on cognitive performance, neuromotor outcomes, or somatic growth of the study participants at ages 2 or 5 years.

Objective

To investigate whether early high-dose RHEpo improves behavioral outcomes and health-related quality of life (HRQoL) at age 5 years.

Design, Setting, and Participants

This was a prespecified secondary analysis of the double-blind, placebo-controlled, multicenter Swiss EPO Neuroprotection randomized clinical trial, which was conducted at 5 level-III perinatal centers in Switzerland. Infants born between 26 weeks 0 days’ and 31 weeks 6 days’ gestation were recruited between 2005 and 2012 and followed-up until age 5 years (last follow-up in 2018). Data were analyzed from January 6 to December 31, 2021.

Interventions

Infants were assigned to receive either RHEpo (3000 IU/kg) or placebo (saline, 0.9%) intravenously 3 times within the first 42 hours after birth.

Main Outcomes and Measures

The prespecified parent-reported measures of behavioral outcomes and health-related quality of life (HRQoL) of their children at the age of 5 years were assessed by two standardized questionnaires: the Strengths and Difficulties Questionnaire (behavioral outcomes) and the KIDSCREEN-27 (HRQoL).

Results

Among 448 randomized infants, 228 infants were assigned to the RHEpo group and 220 infants were assigned to the placebo group. Questionnaire data were available for 317 children (71%) at a mean (SD) age of 5.8 (0.4) years (mean [SD] gestational age at birth, 29.3 [1.6] weeks; mean [SD] birth weight 1220 [340] grams; 128 [40%] female infants). At the age 5 years follow-up, the mean (SD) total difficulties score in the RHEpo group (8.41 [5.60] points) was similar to that of the placebo group (7.76 [4.81]) (P = .37). There were no statistically significant differences between the groups in any other outcome measures.

Conclusions and Relevance

This secondary analysis of a randomized clinical trial showed no evidence for an effect of early high-dose RHEpo administration on behavioral outcomes or HRQoL in children born very preterm at early school age.

Trial Registration

ClinicalTrials.gov Identifier: NCT00413946